Welcome to our dedicated page for GH Research PLC Ordinary Shares news (Ticker: GHRS), a resource for investors and traders seeking the latest updates and insights on GH Research PLC Ordinary Shares stock.
GH Research PLC is a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of psychiatric and neurological disorders. The company is dedicated to developing innovative therapies for managing mental illnesses, particularly focusing on Treatment-Resistant Depression (TRD). Their primary therapeutic candidate is Mebufotenin 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT), a novel and proprietary compound aimed at providing relief for patients who have not responded to conventional treatments.
GH Research PLC has been making significant strides in clinical trials, evaluating the safety and efficacy of their 5-MeO-DMT therapies. By leveraging cutting-edge science and a patient-centered approach, the company aims to address the urgent need for effective treatment options in the mental health space.
Recent achievements include successful completion of early-phase trials, with promising data supporting the potential of 5-MeO-DMT as a breakthrough therapy for TRD. These advancements highlight the company's commitment to bringing transformative solutions to market, improving the lives of patients who suffer from severe mental health conditions.
Financially, GH Research PLC remains well-positioned to continue its research and development efforts, thanks to a robust funding strategy and strategic partnerships with leading institutions in the pharmaceutical and biotech industries. The company's investor relations are managed by Julie Ryan, and they actively communicate updates and achievements to stakeholders.
For those seeking the latest updates on GH Research PLC's performance, events, and developments, their investor relations team can be contacted at investors@ghres.com.
GH Research has completed enrollment for its Phase 2b trial of GH001 (inhaled mebufotenin) in treatment-resistant depression, with top-line data expected by Q1 2025. The company reported $193.8 million in cash and equivalents as of September 30, 2024, down from $222.7 million at end-2023. Q3 2024 saw increased R&D expenses of $8.4 million (vs $7.1M in Q3 2023) and G&A expenses of $4.2 million (vs $2.6M in Q3 2023), resulting in a net loss of $12.1 million ($0.23 per share). The FDA clinical hold on GH001's IND continues, with ongoing nonclinical studies addressing inhalation toxicology concerns.
GH Research PLC (Nasdaq: GHRS) reported Q2 2024 financial results and provided business updates. Key highlights include:
1. Phase 2b trial of GH001 for treatment-resistant depression (TRD) on track for completion in Q3 2024.
2. Phase 1 trial for proprietary aerosol delivery device approved in the UK and recruiting.
3. Cash position of $204.5 million as of June 30, 2024.
4. R&D expenses increased to $9.8 million in Q2 2024 from $7.2 million in Q2 2023.
5. Net loss of $10.4 million ($0.20 per share) in Q2 2024 compared to $7.7 million ($0.15 per share) in Q2 2023.
6. FDA clinical hold on GH001 IND continues, with ongoing nonclinical studies to address inhalation toxicology concerns.
GH Research PLC (Nasdaq: GHRS) has announced the promotion of Dr. Velichka "Villy" Valcheva to Chief Executive Officer, succeeding co-founder PD Dr. med. Theis Terwey. Dr. Valcheva, who joined the company in August 2023 and has served as Chief Medical Officer since February 2024, brings over 20 years of pharmaceutical and biotech industry leadership experience.
The company is currently screening patients for its phase 2b trial in treatment-resistant depression, with enrollment expected to complete in September 2024. Additionally, a phase 1 healthy volunteer study using GH Research's proprietary device is actively enrolling in the UK. These developments signify the company's progress in its mission to transform the treatment of psychiatric and neurological disorders.
GH Research PLC reported financial results for Q1 2024, with cash reserves of $214.0 million expected to last until 2026. The Phase 2b trial of GH001 for treatment-resistant depression is progressing, with top-line data expected in late 2024. GH002, the intravenous product candidate, showed promising results in a Phase 1 trial. The company provided updates on IND for GH001 and financial highlights.
FAQ
What is the current stock price of GH Research PLC Ordinary Shares (GHRS)?
What is the market cap of GH Research PLC Ordinary Shares (GHRS)?
What does GH Research PLC specialize in?
What is 5-MeO-DMT?
What stage is GH Research PLC's lead therapy in?
Who manages GH Research PLC's investor relations?
What recent achievements has GH Research PLC made?
What are GH Research PLC’s core business activities?
How can I stay updated on GH Research PLC's developments?
What is the focus of GH Research PLC’s clinical research?
How does GH Research PLC contribute to mental health treatment?
Who can benefit from GH Research PLC’s therapies?
